Haystack MRD Detects Colorectal Cancer Recurrence, Study Reports

The Haystack MRD ctDNA liquid biopsy test accurately detects colorectal cancer recurrence with 100% specificity and outperforms standard CEA testing, showing strong clinical and analytical performance in stage II and III patients from the DYNAMIC trials. The test is FDA Breakthrough Designated and available through Quest Diagnostics across the US.

This Wire brief sits within Fusion42's coverage of Diagnostics, and 2 sources have reported it between 1 Oct 2026 and 5 Oct 2026.